TerSera Therapeutics LLC, a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2015, the company has rapidly established itself as a leader in developing innovative therapies for patients with unmet medical needs, particularly in the areas of oncology and rare diseases. With a focus on precision medicine, TerSera's core products include advanced therapeutics that leverage cutting-edge research and technology, setting them apart in a competitive market. The company has achieved significant milestones, including strategic partnerships and successful product launches, which have solidified its position as a trusted name in the healthcare sector. TerSera Therapeutics continues to drive advancements in treatment options, demonstrating a commitment to improving patient outcomes and enhancing the quality of life for those they serve.
How does TerSera Therapeutics LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
TerSera Therapeutics LLC's score of 23 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
TerSera Therapeutics LLC, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that TerSera may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives at this time. As the company operates within a sector increasingly focused on sustainability, it may benefit from developing clear climate strategies and targets to align with broader industry trends and expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
TerSera Therapeutics LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
